Dr. Xiaoting Hua: Groundbreaking Findings on Cefiderocol Resistance in Acinetobacter baumannii 丨ECCMID 2023

Dr. Xiaoting Hua: Groundbreaking Findings on Cefiderocol Resistance in Acinetobacter baumannii 丨ECCMID 2023

At the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2023) held in Copenhagen, Dr. Xiaoting Hua of the Sir Run Run Shaw Hospital affiliated with Zhejiang University School of Medicine unveiled significant findings. His research focused on mutations that mediate Acinetobacter baumannii's resistance and virulence to a new antibiotic, Cefiderocol.
Dr. Yimin Wang: Advances in Ventilator-Associated Pneumonia Research丨ECCMID 2023

Dr. Yimin Wang: Advances in Ventilator-Associated Pneumonia Research丨ECCMID 2023

Ventilator-Associated Pneumonia (VAP) continues to be a critical concern in intensive care units, leading to prolonged hospital stays and increased mortality rates. The European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2023 unveiled crucial research findings shedding light on innovative approaches to VAP diagnosis and treatment. In this article, we present a synthesis of the key discoveries from ECCMID 2023, offering insights into the evolving landscape of VAP research.
Interview with Chao Zhuo at ECCMID 2023

Interview with Chao Zhuo at ECCMID 2023

The 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) took place in Copenhagen, Denmark, from April 15th to 18th, 2023. As one of the most significant conferences in the field of clinical microbiology and infectious diseases, it marked a significant gathering after a three-year hiatus due to the pandemic. Chinese experts, including Dr. Chao Zhuo from The First Affiliated Hospital of Guangzhou Medical University, were present to share their insights.
Dr. Graham Taylor: Understanding and Combatting HTLV-1丨ECCMID 2023

Dr. Graham Taylor: Understanding and Combatting HTLV-1丨ECCMID 2023

HTLV-1, a retrovirus closely associated with certain forms of cancer, remains a lesser-known but significant global health concern. Despite its considerable impact on populations around the world, there is a lack of attention and understanding regarding this infection. This article sheds light on the challenges posed by HTLV-1 and emphasizes the need for increased awareness, research, and interventions.
Antimicrobial Susceptibility Testing: The Joint Efforts of CLSI and EUCAST丨ECCMID 2023

Antimicrobial Susceptibility Testing: The Joint Efforts of CLSI and EUCAST丨ECCMID 2023

Antimicrobial susceptibility testing (AST) is pivotal in both individualized and empirical treatments. Notably, standards set for interpreting AST results enable clinicians to choose suitable medications and optimal treatment plans, acting as a significant tool in controlling antimicrobial resistance. The most influential bodies in this space are the Clinical and Laboratory Standards Institute (CLSI) of the United States and the European Committee on Antimicrobial Susceptibility Testing (EUCAST). These entities aim to standardize AST procedures and reduce experimental errors.
Dr. Biao Zhu: Common Comorbidities in HIV Patients and Their Antiretroviral Therapy

Dr. Biao Zhu: Common Comorbidities in HIV Patients and Their Antiretroviral Therapy

Although antiretroviral therapy (ART) has greatly reduced the mortality associated with HIV, the morbidity of non-AIDS-related complications associated with HIV remains high. Therefore, it is crucial to understand and assess clinical decision factors for adjusting ART in the context of suppressed HIV RNA. At the recently concluded 12th International AIDS Society HIV Science Conference ( IAS 2023), Dr. A. Cozzi-Lepri of University College London reported a study (Abstract number: EPB0169) that analyzed and evaluated the risk of ART switches in the context of common comorbidities combined with HIV and suppressed HIV RNA. This journal specially invited Dr. Biao Zhu from the First Affiliated Hospital of Zhejiang University School of Medicine, China, to provide a brilliant review of this research.
Dr. Hui Wang: Second-line treatment choice for children with HIV infection

Dr. Hui Wang: Second-line treatment choice for children with HIV infection

Currently, the choice of second-line antiretroviral therapy (ART) for children infected with HIV is extremely limited. At the12th International AIDS Society HIV Science Conference (IAS 2023), researchers announced the results of a significant clinical study, the CHAPAS-4 ( Abstract No. OALBB0503), focusing on the long-term treatment outcomes of second-line therapy in children with HIV infections. We specially invited Dr. Hui Wang from the Affiliated Second Hospital of Southern University of Science and Technology, China, to provide a brilliant review of this research.
Dr. YunHe: The Impact of Rapid ART Initiation on HIV Outcomes

Dr. YunHe: The Impact of Rapid ART Initiation on HIV Outcomes

The concept of rapid initiation of antiretroviral therapy (ART) has been proposed for nearly 10 years, and many studies have confirmed the long-term benefits of rapid ART initiation. At the 12th International AIDS Society HIV Science Conference (IAS 2023), Thai scholar Sirinya Teeraananchai reported a study on the impact of rapid ART initiation on the health outcomes of People Living with HIV (PLWH). Dr.Yun He from the Third People's Hospital of Shenzhen, China, was specially invited to comment on the study as follows.
Dr. WeiCao: Focus on Managing HIV Complications, Further Improving Patient Survival

Dr. WeiCao: Focus on Managing HIV Complications, Further Improving Patient Survival

The 12th International AIDS Society Conference on HIV Science (IAS 2023) was held from July 23-26, 2023, in Brisbane, Australia. As the largest open scientific conference in the global field of HIV/AIDS, it attracted the participation of experts, medical professionals, community organizations, and healthcare companies worldwide. Dr. Wei Cao from Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, was invited to attend the conference and was interviewed on-site by Infectious Disease Frontier. We have invited Dr. Cao to share the latest developments emerging from this conference and hot topics related to HIV/AIDS treatment.
Dr.HongzhouLu: NAD Management is Key for HIV Patients, Not Just Changing Medication

Dr.HongzhouLu: NAD Management is Key for HIV Patients, Not Just Changing Medication

The use of highly active antiretroviral therapy (HAART) has led to effective virological control in HIV-infected individuals, significantly reducing mortality rates and transforming AIDS into a treatable and manageable chronic disease. Today, one of the main clinical challenges is how to choose more "efficient and less toxic" treatment options to improve patients' quality of life. At the 12th International AIDS Society HIV Science Conference (IAS 2023) held recently, the first randomized controlled trial on switching to integrase strand transfer inhibitor (INSTI)-based therapy to control weight gain was reported. Infectious Disease Frontier invited Dr. Hongzhou Lu from Shenzhen Third People's Hospital, China, to interpret this trial and share insights into the current and future management of non-AIDS defining diseases (NAD) in HIV-infected individuals.